In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Argan, Inc.’s current price exceeds weighted fair value by 45%, indicating potential overvaluation amid high confidence in estimates. Strong financial health contrasts with Monte Carlo’s wide valuation range and 100% downside risk scenarios below the current price, reflecting significant volatility and valuation uncertainty. Analyst targets and trading range suggest optimism but differ markedly from DCF and EV/EBITDA valuations.